Coya Therapeutics Begins Extension Phase of ALSTARS Trial for COYA 302

Coya Therapeutics Initiates ALSTARS Trial Extension Phase for ALS Drug

Coya Therapeutics has initiated the blinded extension phase of its Phase II ALSTARS trial for COYA 302, an investigational biologic therapy for amyotrophic lateral sclerosis (ALS). Following an initial 24-week placebo-controlled, double-blind phase, participants who completed this stage continue their assigned regimen. Those originally on placebo are re-randomized to one of two COYA 302 dosing regimens for up to an additional 24 weeks, allowing for the collection of up to 48 weeks of safety and efficacy data. The study is being conducted across 20 to 25 sites in Canada and the US.

• The ALSTARS trial features an initial 24-week placebo-controlled, double-blind phase. Upon completion, participants can enter a blinded extension period where those initially on placebo are re-randomized to receive one of two COYA 302 dosing regimens, ensuring all participants eventually receive the active treatment and allowing for extended data collection up to 48 weeks.
• COYA 302 is a proprietary biologic combination therapy designed to enhance regulatory T cell (Treg) function and suppress inflammation driven by monocytes and macrophages. It comprises low-dose interleukin-2 (LD IL-2) and DRL_AB, which is a biosimilar candidate for abatacept, targeting key pathways implicated in neurodegenerative diseases like ALS.
• The trial incorporates standard ALS clinical outcome measures, including the ALS Functional Rating Scale-Revised (ALSFRS-R), neurofilament (NfL), maximal inspiratory pressure (MIP), and slow vital capacity (SVC). Additionally, neurological assessments, biomarker monitoring, and routine safety evaluations through adverse event tracking are integral to the study.

Unpacking the ALSTARS Trial Design and Extension Phase

Recent ALS clinical trials have evolved toward more sophisticated analytical frameworks, with joint modeling demonstrating superior statistical power for analyzing simultaneous effects on survival and function. The field has also recognized significant multidimensionality issues with traditional outcome measures, leading to exploration of alternative endpoints and design modifications that can reduce sample sizes and patient exposure to ineffective treatments.

COYA 302's Treg-Enhancing Approach Beyond ALS

Low-dose interleukin-2 has been investigated across multiple therapeutic areas beyond ALS, with particular focus on autoimmune and inflammatory conditions. No information was found regarding DRL_AB trials in the available literature. The clinical applications span from well-established autoimmune diseases to emerging therapeutic areas, with varying intervention models depending on the specific indication and study design.

Addressing the Persistent Challenges in ALS Treatment

Amyotrophic lateral sclerosis continues to present formidable therapeutic challenges despite decades of intensive research and clinical development efforts. The disease remains incurable and fatal, with no causal or disease-modifying therapies currently available for the majority of patients. Multiple barriers impede effective treatment delivery and limit therapeutic outcomes across the ALS patient population.

• Absence of disease-modifying therapies: No effective therapies exist to meaningfully extend survival or modify disease progression, with decades of clinical trials yielding predominantly negative results until recent breakthroughs in specific patient subsets

• Blood-brain barrier penetration limitations: Current marketed drugs demonstrate poor blood-brain barrier permeability, significantly compromising therapeutic efficacy and contributing to unfavorable patient prognoses

• Diagnostic delays and complexity: The insidious onset and progressive nature of neurodegeneration creates significant challenges for early diagnosis, delaying treatment initiation when therapeutic intervention may be most beneficial

• Limited genetic target applicability: Precision medicine approaches like SOD1-targeted antisense oligonucleotides benefit only a minority of ALS patients who carry specific mutations, restricting broader therapeutic impact

• Inadequate management of behavioral symptoms: Behavioral disorders affect 30-60% of ALS patients and negatively impact prognosis and quality of life, yet clinical management options remain severely limited

• Insufficient understanding of disease heterogeneity: The natural history of behavioral dysfunctions, their relationship to frontotemporal lobe degeneration, and optimal patient selection criteria for emerging therapies remain poorly characterized

• Multidisciplinary care coordination challenges: Effective ALS management requires complex coordination across multiple specialties, particularly when addressing comorbid behavioral disorders alongside motor symptoms